Crispr Therapeutics shares tumble after significant earnings miss
On Monday, JMP Securities maintained a positive outlook on Viant Technology Inc (NASDAQ:DSP) with a Market Outperform rating and a steady price target of $24.00. The stock, currently trading at $14.67, has seen significant volatility, dropping 26% in the past week despite a remarkable 46% gain over the last six months. According to InvestingPro data, analysts maintain a bullish consensus with price targets ranging from $20 to $27. The firm’s confidence is buoyed by the anticipated EO-3021 update expected in the first half of 2025, which is seen as a key milestone for validating the drug’s initial monotherapy data.
JMP Securities highlighted the promising initial response rate from second-quarter 2024 data, noting that it surpassed both their expectations of 38% and the consensus estimate of 35%, albeit from a small patient sample (N=7). This performance positions EO-3021 favorably in comparison to its peers. The company’s strong execution is reflected in its impressive 30% revenue growth over the last twelve months, with InvestingPro analysis indicating robust financial health metrics and a solid balance sheet with more cash than debt.
Despite the potential for EO-3021’s efficacy in CLDN18.2-low or non-expressing patients not materializing—a scenario similar to other antibody-drug conjugates (ADCs)—the firm noted that ELEV’s implementation of a prospective cutoff for future studies has realigned expectations. While this adjustment may have tempered the prospects for targeting the less competitive CLDN18.2-low/no patient group, JMP Securities believes that most investors had not heavily relied on this outcome.
Looking ahead, the first half of 2025 update is anticipated to expand EO-3021’s patient pool significantly. Viant Technology’s progress with EO-3021 is closely watched by investors, as the company aims to establish a strong foothold in the market with its novel treatments. With a market capitalization of $925 million and projected earnings growth, InvestingPro subscribers can access 15+ additional exclusive insights and a comprehensive Pro Research Report, offering deep-dive analysis of Viant’s valuation and growth prospects.
In other recent news, Viant Technology reported impressive fourth-quarter 2024 earnings, exceeding expectations with an earnings per share (EPS) of $0.15, surpassing the projected $0.14. The company also reported a substantial revenue of $90.05 million, significantly higher than the forecasted $52.38 million. Despite these strong financial results, Viant Technology’s stock experienced a 12.15% decline in aftermarket trading. The company announced a 40% year-over-year revenue increase for the quarter, underscoring its robust financial performance. Viant Technology has been actively investing in AI and strategic acquisitions, including the recent purchase of Locker, a data collaboration platform, to enhance its platform capabilities. The company also provided a revenue guidance of $65-68 million for the first quarter of 2025, indicating a 25% year-over-year growth. Analysts from Needham and Concord have shown interest in the strategic direction and potential impact of these acquisitions on Viant’s future growth. Viant Technology continues to focus on expanding its AI capabilities and targeting technologies, particularly in the SMB and direct-to-consumer e-commerce markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.